They are not the first bio-tech to mis-design a trial or two....

They are not the first bio-tech to mis-design a trial or two. Some 90% of prospective drugs and treatments fail to make it to market. Its a high-risk, high reward game we are invested in. MSB themselves have cited the importance of chondrocytes in producing both proteoglycan and collagen crucial to the regeneration involved with Rexlemestrocel-L in its treatment of degenerative disc disease (and other applications for its treatments). There is another Aussie stem-cell company that has been licensed to manufacture chondrocyte cells since 2009 and quietly treating small numbers of patients with collagen and cartilage issues. MSB needs to be talking to them if their Grunenthal partnership does not prohibit.

In a perfect world they'd have been involved from the outset and we'd have a combined trial done and dusted on a mesenchymal/chondrocyte cocktail applied to DDD patients of less than two years on candidates who under MRI were shown to fit the likely guise for treatment success. C'est la vie. We wait.